MarketInOut Stock Screener Log In | Sign Up

AIM ImmunoTech Inc

NYSE • Healthcare • Biotechnology • Quote as of 10/30/2026
AIM ImmunoTech Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization6.63 mln
Float37.18 mln
Earnings Date11/17/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-3.14
Reliable

Relative Strength

9 / 100
Severely lagging

Debt / Equity

0.51
Moderate leverage

Pre-Tax Margin

-15,021%
Severely loss-making

ROE

-2,382
Deeply negative

Business Description

AIM ImmunoTech Inc. is a US-based medical research company working to develop treatments for cancer, viral infections, and immune system disorders. Its two main products are Ampligen, used to treat chronic fatigue syndrome, and Alferon N Injection, which targets genital warts. The company is also exploring Ampligen as a potential therapy for a wide range of cancers and conditions including HIV, Hepatitis B, and COVID-19. Founded in 1966 and based in Ocala, Florida, the company operated under the name Hemispherx Biopharma Inc. before rebranding in 2019.

Key Fundamentals

EPS-2.98
ROE-2,382
RPS0.01
ROIC-173
ROA-194
Interest Cover-9.72
EBITDA, mln-12.46
EV / EBITDA0.19
EV / EBIT0.18
Revenue, mln0.09

Quote Details

Last 0.1545
Change -0.0065 (-4.04%)
Open 0.164
Volume 316,845
Turnover 48,953
Average Volume 527,944

Financial Ratios

Pre-Tax Profit Margin-15,021
Leverage Ratio1.64
Current Ratio2.11
Price / Book0.66
Price / Tangible Book0.85
Debt / Equity0.51
Price / Sales6.84
PEG Ratio0.71

Financial Strength

Altman Z-Score-51.28
Piotroski F-Score 3 / 9
Beneish M-Score-3.14
Short Ratio0.12
Short % of Float3.55

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -1.15% 26 / 100   
1 Month -17.69% 7 / 100   
2 Months -38.2% 3 / 100   
6 Months -70.02% 1 / 100   
1 Year -93.31% 1 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog